Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
Why is this work in the frame?
A frame that forgets how it found something cannot be audited. These are the routes that admitted this work.
Abstract
BACKGROUND: Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure in patients regardless of the presence or absence of diabetes. More evidence is needed regarding the effects of these drugs in patients across the broad spectrum of heart failure, including those with a markedly reduced ejection fraction. METHODS: In this double-blind trial, we randomly assigned 3730 patients with class II, III, or IV heart failure and an ejection fraction of 40% or less to receive empagliflozin (10 mg once daily) or placebo, in addition to recommended therapy. The primary outcome was a composite of cardiovascular death or hospitalization for worsening heart failure. RESULTS: of body-surface area per year, P<0.001), and empagliflozin-treated patients had a lower risk of serious renal outcomes. Uncomplicated genital tract infection was reported more frequently with empagliflozin. CONCLUSIONS: Among patients receiving recommended therapy for heart failure, those in the empagliflozin group had a lower risk of cardiovascular death or hospitalization for heart failure than those in the placebo group, regardless of the presence or absence of diabetes. (Funded by Boehringer Ingelheim and Eli Lilly; EMPEROR-Reduced ClinicalTrials.gov number, NCT03057977.).
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
The record
- Venue
- New England Journal of Medicine
- Topic
- Diabetes Treatment and Management
- Field
- Medicine
- Canadian institutions
- Boehringer Ingelheim (Canada)University of TorontoMcGill University Health CentreSt. Michael's Hospital
- Funders
- Eli Lilly and CompanyBoehringer Ingelheim
- Keywords
- EmpagliflozinHeart failureMedicineEjection fractionCardiologyDiabetes mellitusInternal medicineBenzhydryl compoundsBroad spectrumHeart failure with preserved ejection fractionType 2 diabetesEndocrinologyChemistry
- Has abstract in OpenAlex
- yes